Chih-Yi Liao
Overview
Explore the profile of Chih-Yi Liao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
275
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gujarathi R, Klein J, Liao C, Pillai A
Clin Liver Dis
. 2024 Nov;
29(1):1-15.
PMID: 39608950
The epidemiology of hepatocellular carcinoma (HCC) has shifted significantly in the last 2 decades with non-viral etiologies such as metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease on the...
2.
Yu Q, Mahbubani A, Kwak D, Liao C, Pillai A, Patel M, et al.
J Vasc Interv Radiol
. 2024 Nov;
36(3):489-498.e3.
PMID: 39491643
Purpose: To determine effectiveness of radiofrequency ablation for treatment of intrahepatic cholangiocarcinoma (iCCA) using a population-based database. Materials And Methods: Data were extracted from Surveillance, Epidemiology, and End Results (SEER)...
3.
Tobias J, Azar S, Gujarathi R, Nordgren R, Vaghaiwalla T, Millis J, et al.
Surgery
. 2024 Oct;
177:108834.
PMID: 39395860
Background: With the advent of peptide receptor radionuclide therapy, the timing and sequence of surgery in the treatment of metastatic gastroenteropancreatic neuroendocrine tumors merits further study. We hypothesized that surgery...
4.
Gujarathi R, Tobias J, Azar S, Keutgen X, Liao C
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272851
Peptide Receptor Radionuclide Therapy (PRRT), a form of Radioligand Therapy (RLT), and Capecitabine/Temozolomide (CAPTEM) are cornerstones of systemic therapy for metastatic pancreatic neuroendocrine tumors (PNETs). Data regarding comparative efficacy are...
5.
Gujarathi R, Franses J, Pillai A, Liao C
Front Oncol
. 2024 Sep;
14:1432423.
PMID: 39267840
Targeted therapies are the mainstay of systemic therapies for patients with advanced, unresectable, or metastatic hepatocellular carcinoma. Several therapeutic targets, such as c-Met, TGF-β, and FGFR, have been evaluated in...
6.
Gujarathi R, Azar S, Tobias J, Polite B, Setia N, Feinberg N, et al.
Endocr Relat Cancer
. 2024 Aug;
31(11).
PMID: 39093924
Pre-clinical data suggest that mutations in the MEN1, DAXX, and/or ATRX genes may potentially increase radiation efficacy in cancer cells. Herein, we explore the association between response to peptide receptor...
7.
Azad N, Hu Z, Sahin I, Iyer R, Aranha O, Hochster H, et al.
Future Oncol
. 2024 Jun;
20(30):2241-2248.
PMID: 38861293
Treatment options for patients with biliary tract cancer are limited, and the prognosis is poor. CTX-009, a novel bispecific antibody targeting both DLL4 and VEGF-A, has demonstrated antitumor activity in...
8.
Belmont E, Bansal V, Yousef M, Zeineddine M, Su D, Dhiman A, et al.
JCO Precis Oncol
. 2024 May;
8:e2300531.
PMID: 38723230
Purpose: Conventional surveillance methods are poorly sensitive for monitoring appendiceal cancers (AC). This study investigated the utility of circulating tumor DNA (ctDNA) in evaluating systemic therapy response and recurrence after...
9.
Rappaport A, Kyi C, Lane M, Hart M, Johnson M, Henick B, et al.
Nat Med
. 2024 Mar;
30(4):1013-1022.
PMID: 38538867
Therapeutic vaccines that elicit cytotoxic T cell responses targeting tumor-specific neoantigens hold promise for providing long-term clinical benefit to patients with cancer. Here we evaluated safety and tolerability of a...
10.
Yu Q, Wang Y, Ungchusri E, Pillai A, Liao C, Fung J, et al.
J Vasc Interv Radiol
. 2024 Mar;
35(7):989-997.e2.
PMID: 38490364
Purpose: To assess the safety and effectiveness of using modified radiation lobectomy (mRL) to treat primary hepatic tumors located in the right hepatic lobe (Segments V-VIII) and to determine future...